A study published in the Anticancer Research journal, a peer-reviewed medical journal published by the International Institute of Anticancer Research, found that a unique turmeric extract known as liposomal curcumin may provide an alternative to chemotherapy in the treatment of lethal pancreatic cancers.
If you're familiar with turmeric, you probably know that most of its health benefits are due to its main active ingredient, curcumin. Curcumin is a potent anti-inflammatory that has shown to increase cognition, reduce LDL cholesterol, help fight arthritis and reduce the risk of cancer. As the primary polyphenol in turmeric, curcumin has been studied extensively for its ability to kill cancer cells. It has been found to inhibit the proliferation of tumor cells, inhibit the transformation of cells from normal to tumor, decrease inflammation, help prevent the development of additional blood supply necessary for cancer cell growth (angiogenesis) and help the body destroy mutated cells to prevent them from spreading throughout the body.
Lipsomal curcumin uses a lipid-based drug delivery system that has seen success. The main disadvantage associated with curcumin in the past was its poor solubility. When curcumin is encapsulated into liposomes, the ability to gain entry into the body by passing through barriers in the liver is greatly improved.
Known for responding poorly to conventional treatment, exocrine pancreatic cancer statistics declare only a 14% 5-year survival rate in Stage IA cancers. That percentage is reduced to just 1% in Stage IV types. Even when chemotherapy, radiation, surgery and radiotherapy are able to debulk the tumor, recurrence is common.